empty
 
 
rs
Search
Podrška
Trenutno otvaranje računa
Trgovačka platforma
Depozit/Povlačenje
Search
Za početnike Za trgovce Za partnere Idi na pauzu About InstaSpot
rs
#DHR Nazad na listu instrumenata #DXCM

Menjač valuta

Dynavax Technologies Corporation
15.49 USD
23 Jan 2026 22:59
Promena cene (% chg)
$-0.04
(-0.26%)
Cena prethodnog zatvaranja
Cena prethodnog zatvaranja

Cena zatvaranja prethodnog dana.
$15.63
Otvaranje
Otvaranje

Cena na otvaranju.
$15.67
Dnevni maksimum
Dnevni maksimum

Najviša cena tokom poslednjeg dana trgovine.
$15.64
Dnevni minimum
Dnevni minimum

Najniža cena tokom poslednjeg dana trgovine
$15.49
Maksimum u 52 nedelje
Maksimum u 52 nedelje

Opseg najviših cena u poslednje 52 nedelje
$15.66
Minimum u 52 nedelje
Minimum u 52 nedelje

Opseg najnižinih cena u poslednje 52 nedelje
$15.49
Preuzmi arhivu
Buy
15.49
Sell
15.49
Otvori grafikon za pregled na celom ekranu
Buy
15.49
Sell
15.49
Preuzmi arhivu
Otvori grafikon za pregled na celom ekranu

Dynavax Technologies Corporation. About company

Dynavax Technologies Corporation is a biopharmaceutical company whose core business is the development and production of vaccines.

The company’s main product is a hepatitis B drug. The company also produces vaccines against coronavirus, influenza, plague, and other infectious diseases.

In addition, the company is mainly focused on the production of adjuvants. These substances help vaccines to be better absorbed by the body.

Currently, Dynavax has a market capitalization of $1.37 billion. Last year, the company posted revenues of $438.24 million and a net income of $76.71 million.

Dynavax Technologies Corporation’s shares and what affects their price

Dynavax shares have been trading on the NASDAQ exchange under the DVAX ticker since 2004. The initial price per share stood at $7.50.

Currently, the company’s shares are trading between $10 and $12. During the year, the share price was hovering between $7 and $22. At the same time, the company does not pay dividends to its shareholders.

What to pay attention to when trading the company’s shares:

  • Long-term growth prospects are driven by a large number of innovative developments;
  • The target price for the stock is several times higher than the current one, ranging between $45.5 and $48, according to forecasts;
  • Adjuvant technology is an advantage for the company since these additional substances significantly enhance the effect of the vaccines.

Ne možete da razgovarate sada?
Postavite pitanje kroz ćaskanje.